Skip to main content

Day: April 23, 2024

Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2024

BANNOCKBURN, Ill., April 23, 2024 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results and HighlightsNet revenue of $1,146.1 million, up 12.8% compared to $1,015.8 million in the first quarter of 2023 Gross profit of $238.5 million, or 20.8% of net revenue, up 4.1% compared to $229.0 million, or 22.5% of net revenue, in the first quarter of 2023 Net income of $44.8 million, or $0.26 earnings per share, up 14.2% compared to net income of $39.2 million, or $0.21 diluted earnings per share, in the first quarter of 2023 Adjusted EBITDA of $98.3 million, up 4.8% compared to $93.8 million...

Continue reading

Metasphere Labs Inc. Unveils Bitcoin-Based Identity System, and Enters Exclusive Licensing Talks with Bot Ventures Inc.

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) — Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., “Metasphere” or the “Company“) (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is proud to announce an initiative to develop a pioneering bitcoin-based identity system, leveraging the “Spaces Protocol” to enable decentralized digital identities. This system uses Bitcoin’s infrastructure to offer a scalable and permissionless identity framework, enhancing online authenticity and security. Combatting AI-Driven Spam and Disinformation In response to the growing challenge of AI-driven spam and disinformation, Metasphere’s new system aims to authenticate real human and multimedia interactions. This initiative is a key step toward ensuring the integrity of online content and...

Continue reading

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 – $390 million –– Abiprubart Phase 2b trial in Sjögren’s Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution. “One of the drivers of strong ARCALYST growth is an expanding...

Continue reading

Midland Amends Its Lithium Option Agreement With Rio Tinto With the Addition of the Wookie Project

Figure 1MD-RTEC Option for LithiumFigure 2Wookie ProjectMONTREAL, April 23, 2024 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), is pleased to announce the execution of an amended option agreement on April 22, 2024 (the “Option Agreement”) with Rio Tinto Exploration Canada Inc. (“RTEC”) and the addition of the Wookie project to the option agreement signed with RTEC in June 2023 (see press release by Midland dated June 14, 2023). The Wookie project is located in Eeyou Istchee James Bay area. The amended option agreement now consists of eleven (11) projects totalling 2,208 claims covering a surface of about 1,139 square kilometres. These projects include Galinée, Corvette, Mythril East, Chisaayuu, Moria, Shire, Komo, Warp, Sulu, Picard and Wookie (the “Properties”). Highlights:Addition of...

Continue reading

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1 BASKING RIDGE, N.J. and JINAN, China, April 23, 2024 (GLOBE NEWSWIRE) —  Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Qilu Pharmaceutical Co., Ltd. (“Qilu”), one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes both finished products and active pharmaceutical ingredients, announced that the first patient has been treated in Qilu’s Phase 2 trial in China evaluating LSTA1 (also known as “CEND-1”), Lisata’s lead product candidate, in combination with standard-of-care (“SoC”) chemotherapy as a first-line...

Continue reading

KellyOCG Earns Recognition as a John Deere “Partner-level Supplier”

TROY, Mich., April 23, 2024 (GLOBE NEWSWIRE) — KellyOCG, the outsourcing and consulting group of Kelly (Nasdaq: KELYA, KELYB), has earned recognition as a Partner-level supplier for 2023 in the John Deere Achieving Excellence Program. The Partner-level status is Deere & Company’s highest supplier rating. KellyOCG is a supplier of Managed Service Provider (MSP) and Recruitment Process Outsourcing (RPO) solutions to John Deere’s operation in the U.S. and Canada. It was selected for the honor in recognition of its dedication to providing products and service of outstanding quality as well as its commitment to continuous improvement. In addition, KellyOCG has earned recognition for 2023 in the John Deere Cost Reduction Opportunities Process (JD CROP). JD CROP, a supplier suggestion process, is part of Deere & Company’s Achieving...

Continue reading

BULGOLD Announces Filing of Fourth Quarter Financial Results for Three and Twelve Months Ended December 31, 2023

TORONTO, April 23, 2024 (GLOBE NEWSWIRE) — BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to announce that it has filed its audited condensed interim financial statements and MD&A for the fourth quarter and year ended December 31, 2023. During the three months ended December 31, 2023, the Company incurred a net loss of $264,578 ($0.01 per share). For the year ending December 31, 2023, the company incurred a net loss of $1,873,160 ($0.08 per share), including a non-cash expense of $734,269 being the cost of listing (the cost of listing relates to the recently completed acquisition of assets in Bulgaria). Other expenses incurred, primarily related to professional fees for the completion of the acquisition. On December 31, 2023, the company had cash (and cash equivalents) of $2,015,716 (net working capital...

Continue reading

AGF Investments Announces April 2024 Cash Distributions for AGF Enhanced U.S. Equity Income Fund, AGF Total Return Bond Fund and AGF Systematic Global Infrastructure ETF

TORONTO, April 23, 2024 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) (TSX:AGF.B) today announced the April 2024 cash distributions for AGF Enhanced U.S. Equity Income Fund*, AGF Total Return Bond Fund* and AGF Systematic Global Infrastructure ETF, which pay monthly distributions. Unitholders of record on May 1, 2024 will receive cash distributions payable on May 7, 2024. Details regarding the final “per unit” distribution amounts are as follows:ETF Ticker Exchange Cash Distribution Per Unit ($)AGF Enhanced U.S. Equity Income Fund* AENU Cboe Canada Inc. $ 0.130232AGF Total Return Bond Fund* ATRB Cboe Canada Inc. $ 0.080000AGF Systematic Global Infrastructure ETF QIF Cboe Canada Inc. $ 0.123150*AGF Enhanced U.S. Equity Income Fund and AGF Total Return Bond Fund are mutual funds with an ETF series option. Further...

Continue reading

Dime Community Bancshares, Inc. Reports First Quarter 2024 Results With Earnings Per Share Increasing By 11% Versus the Prior Quarter

Core Deposit Growth of 19% Annualized Versus Year End Dime Has Been Executing on Growth Plan And Has Recruited Numerous Talented Groups of Bankers to Position Itself for Future Growth Capital Ratios Continue to Increase and Asset Quality Remains Stable HAUPPAUGE, N.Y., April 23, 2024 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today reported net income available to common stockholders of $15.9 million for the quarter ended March 31, 2024, or $0.41 per diluted common share, compared to $14.5 million, or $0.37 per diluted common share, for the quarter ended December 31, 2023, and $35.5 million, or $0.92 per diluted common share for the quarter ended March 31, 2023. Stuart H. Lubow, President and Chief Executive Officer (“CEO”)...

Continue reading

Manhattan Bridge Capital, Inc. Reports First Quarter Results for 2024

GREAT NECK, N.Y., April 23, 2024 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) announced today that its net income for the three months ended March 31, 2024 was approximately $1,476,000, or $0.13 per share (based on approximately 11.4 million weighted-average outstanding common shares), compared to approximately $1,260,000, or $0.11 per share (based on approximately 11.5 million weighted-average outstanding common shares) for the three months ended March 31, 2023, an increase of $216,000, or 17.1%. This increase is primarily attributable to an increase in interest income from loans and a decrease in general and administrative expenses, partially offset by an increase in interest expense. Total revenues for the three months ended March 31, 2024 were approximately $2,573,000 compared to approximately $2,398,000...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.